Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells
- G. B. Gelaleti,
- T. F. Borin,
- L. B. Maschio-Signorini,
- M. G. Moschetta,
- E. Hellmén,
- A. M. Viloria-Petit(corresponding author)
- Faculdade de Medicina de São José do Rio Preto,
- Universidade Estadual Paulista Júlio de Mesquita Filho,
- Augusta University,
- Swedish University of Agricultural Sciences,
- University of Guelph
Abstract
Background: Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cells. Aim: The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures. Materials and Methods: The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array. Results: Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments. Conclusion: This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 1572-1584 (13 pages)Journal (Volume, Issue Number)
Veterinary and Comparative Oncology (Volume 15, Issue 4)Publication milestones
- Published - 12/2017
Publication status
ISSN
1476-5810Publication IDs
- Scopus: 85016392441
- PubMed: 28322030
